BioSpace News Archive

Drug Development

Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies

December 5, 2020
·
5 min read
Drug Development

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 2 Zella 201 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Acute Myeloid Leukemia at 62nd ASH Annual Meeting

Additional Presentations Provide Updates on Development Programs for Investigational Agents TP-3654 and Dubermatinib

December 5, 2020
·
9 min read
Biotech Beach

New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial

Unparalleled 44 Percent Estimated Four-Year Overall Survival Rate Among Refractory Large B-cell Lymphoma Patients After a Single Infusion of Yescarta

December 5, 2020
·
11 min read
Biotech Beach

Bioniz Announces Positive Clinical Data of BNZ-1, First Anti-Cytokine Therapy to Demonstrate Efficacy in Treating Refractory Cutaneous T-Cell Lymphoma

BNZ-1 showed an overall response rate (ORR) of 63.2% based on the Global Response Score (GRS) in a heavily pretreated, relapsed and refractory CTCL patient population

December 5, 2020
·
6 min read
Genetown

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

The New England Journal of Medicine publishes CTX001 manuscript containing the first report of investigational use of CRISPR/Cas9-based gene editing to treat inherited diseases in humans

December 5, 2020
·
15 min read
BioMidwest

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

AbbVie announced new data from the Phase 2 CAPTIVATE clinical trial evaluating IMBRUVICA® in combination with VENCLEXTA®/VENCLYXTO® in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma during an oral presentation session at the virtual 2020 American Society of Hematology Annual Meeting.

December 5, 2020
·
22 min read
Drug Development

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting

Superiority head-to-head Phase 3 trial of LOXO-305 vs. investigator’s choice of covalent BTK inhibitor in relapsed-refractory mantle cell lymphoma to be initiated in Q1 2021

December 5, 2020
·
10 min read
Biotech Beach

Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study

Primary Analysis Supports Supplemental Biologics License Application (sBLA) for Yescarta Currently Under Priority Review by the U.S. Food & Drug Administration (FDA)

December 5, 2020
·
13 min read
Genetown

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Longer-term data from Phase 1 CRB-401 study evaluating ide-cel in relapsed and refractory multiple myeloma show ongoing deep and durable responses and median overall survival of 34.2 months

December 5, 2020
·
17 min read
Deals

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures Most Patients

December 5, 2020
·
11 min read